Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the …

BM Demaerschalk, DO Kleindorfer, OM Adeoye… - Stroke, 2016 - Am Heart Assoc
Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Hemorrhagic stroke

A Montaño, DF Hanley, JC Hemphill III - Handbook of clinical neurology, 2021 - Elsevier
Hemorrhagic stroke comprises about 20% of all strokes, with intracerebral hemorrhage
(ICH) being the most common type. Frequency of ICH is increased where hypertension is …

Factors influencing haemorrhagic transformation in ischaemic stroke

J Álvarez-Sabín, O Maisterra, E Santamarina… - The Lancet …, 2013 - thelancet.com
Haemorrhagic transformation (HT) of ischaemic infarction occurs when an area of brain
infarction is stained with blood products, mainly red blood cells. An abnormally permeable …

Absolute and relative contraindications to IV rt-PA for acute ischemic stroke

JE Fugate, AA Rabinstein - The Neurohospitalist, 2015 - journals.sagepub.com
Most of the contraindications to the administration of intravenous (IV) recombinant tissue
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …

Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator

BK Menon, JL Saver, S Prabhakaran, M Reeves… - Stroke, 2012 - Am Heart Assoc
Background and Purpose—There are few validated models for prediction of risk of
symptomatic intracranial hemorrhage (sICH) after intravenous tissue-type plasminogen …

Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and …

T Steiner, M Böhm, M Dichgans, HC Diener… - Clinical Research in …, 2013 - Springer
Dabigatran, apixaban, and rivaroxaban have been approved for primary and secondary
stroke prevention in patients with atrial fibrillation. However, questions have arisen about …

Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator

Y Xian, L Liang, EE Smith, LH Schwamm, MJ Reeves… - Jama, 2012 - jamanetwork.com
Context Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in
ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an …

Society for Neuroscience in Anesthesiology and Critical Care Expert consensus statement: anesthetic management of endovascular treatment for acute ischemic …

PO Talke, D Sharma, EJ Heyer… - Journal of …, 2014 - journals.lww.com
Literature on the anesthetic management of endovascular treatment of acute ischemic stroke
(AIS) is limited. Anesthetic management during these procedures is still mostly dependent …

Thrombolysis in stroke despite contraindications or warnings?

B Frank, JC Grotta, AV Alexandrov, E Bluhmki, P Lyden… - Stroke, 2013 - Am Heart Assoc
Background and Purpose—Intravenous thrombolysis with alteplase is approved for acute
ischemic stroke, but its use is limited by numerous contraindications and warnings arising …

Republished: Society for Neuroscience in Anesthesiology and Critical Care expert consensus statement: Anesthetic management of endovascular treatment for acute …

PO Talke, D Sharma, EJ Heyer, SD Bergese… - Stroke, 2014 - Am Heart Assoc
Literature on the anesthetic management of endovascular treatment of acute ischemic stroke
(AIS) is limited. Anesthetic management during these procedures is still mostly dependent …